Oruka Therapeutics, Inc.
ORKA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.41B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.41 Billion |
|---|---|
| Enterprise Value | $6.15 Billion |
| Earnings per Share | $-2.31 |
| Beta | -0.39 |
| Outstanding Shares | 62,872,318 |
Return
| Return on Equity | -11.92% |
|---|---|
| Return on Assets | -11.66% |
| Return on Invested Capital | -13.89% |
Valuation & Multiples
| P/E Ratio | -39.22 |
|---|---|
| PEG | -57.95 |
| Price to Sales | - |
| Price to Book Ratio | 5.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -39.64 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.52
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.60
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 78.45% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.55%▼ 118.06% |
|---|---|
| Total Invested | $28.88M▼ 99.59% |
| Investors Holding | 42▼ 224.00% |
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D.
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.